BUZZ-Ardelyx rises as it begins late-stage test of constipation drug

Reuters01-28
BUZZ-<a href="https://laohu8.com/S/ARDX">Ardelyx</a> rises as it begins late-stage test of constipation drug

** Shares of drugmaker Ardelyx ARDX.O rise 1.01% to $7.97 premarket

**  Co says it has begun dosing patients in a late-stage trial testing Ibsrela in adults with chronic idiopathic constipation, a long-term condition that causes infrequent or difficult bowel movements

** The  trial will enroll about 700 adults and compare Ibsrela with placebo over 26 weeks; initial results expected in H2 2027, per co

** ARDX's Ibsrela is already approved in the U.S. for irritable bowel syndrome with constipation; co aims to expand use to chronic idiopathic constipation

**  Most common side effects include diarrhea, gas, abdominal swelling and dizziness, co says

** Shares up ~15% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment